Company profile · Biotech & medical
Gongwin Biopharm Holdings
共信醫藥科技控股股份有限公司 · 6617
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
Gongwin Biopharm Holdings researches and develops novel anti-cancer drugs and veterinary pharmaceuticals.[1]
Its products include PTS302 for central airway obstruction caused by lung cancer, PTS100 for liver cancer, PTS-02 for tracheal adenoid cystic carcinoma, and veterinary drugs for melanoma, peripheral nerve sheath tumors, and mast cell tumors.[2]
The company has its operational headquarters in Taipei.[2]
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$9m | +397.3% | +221.7% |
2024-11 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-12 to 2026-11-10 | +NT$73m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | Gongwin Biopharm Holdings Co., Ltd. |
|---|---|
| Chinese name | 共信醫藥科技控股股份有限公司 |
| Stock code | 6617 (TPEx) |
| Industry | Biotech & medical |
| Founded | 27 Mar 2014 |
| Listed | 18 Jun 2024 |
| Paid-in capital | NT$1.3bn |
| Chairman | 吳崇漢 |
| President | 林懋元 |
| Headquarters | 3F, No. 80, Sec. 1, Jianguo North Road, Zongshan Dist. Taipei , Taiwan |
| Website | https://www.gongwinbiopharm.com |
| Official business description | 抗癌消融新藥 |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- MOPS 公司基本資料 共信醫藥科技控股股份有限公司 · mops · retrieved 04 Nov 2026
- Annual report 2025 (English), business scope · annual_report · retrieved 04 Nov 2026
Using it at work? Join the team-plan waiting list